Mark C. Liu

Mark C. Liu

Pulmonary Medicine

5501 Hopkins Bayview Circle, Allergy & Asthma Center, 2nd Floor
Allergy & Asthma Center, 2nd Floor
Baltimore, MD 21224

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: October 21, 2024

Prospective REALITI-A Study: 2-Year Real-World Benefits of Mepolizumab in Severe Asthma.

Prospective REALITI-A Study: 2-Year Real-World Benefits of Mepolizumab in Severe Asthma.

Journal: CHEST pulmonary

Published: September 16, 2024

Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.

Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 23, 2023

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.

Journal: ERJ open research

Published: June 24, 2021

From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

Journal: Allergy

Published: June 04, 2021

Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study.

Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study.

Journal: Chronic obstructive pulmonary diseases (Miami, Fla.)

Published: May 27, 2021

The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions.

The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions.

Journal: The Journal of allergy and clinical immunology

Published: May 20, 2021

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.

Journal: Respiratory research

Published: February 25, 2021

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).

Journal: The European respiratory journal

Published: February 08, 2021

PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment.

PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment.

Journal: The Journal of allergy and clinical immunology

Published: December 08, 2020

The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.

The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.

Journal: Journal of biopharmaceutical statistics

Published: September 17, 2020

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.

Journal: Respiratory research

Published: September 07, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026